marks published for opposition - U.S. Patent and Trademark Office

MAY 29, 2012 U.S. PATENT AND TRADEMARK OFFICE TM 527
CLASS 5—(Continued).
SN 85-333,303. RUPPERT, RICK, REDONDO BEACH, CA.
FILED 5-30-2011.
THE MARK CONSISTS OF STANDARD CHARACTERS
WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,
SIZE, OR COLOR.
FOR DIETARY AND NUTRITIONAL SUPPLEMENTS;
PHARMACEUTICAL PREPARATIONS, NAMELY,
PHARMACEUTICAL PREPARATIONS FOR THE
TREATMENT OF NUTRITIONAL DEFICIENCIES (U.S.
CLS. 6, 18, 44, 46, 51 AND 52).
FIRST USE 4-25-2011; IN COMMERCE 4-26-2011.
JEFFREY LOOK, EXAMINING ATTORNEY
SN 85-335,750. EDWARD WYNN LLC, ARCADIA, CA. FILED
6-1-2011.
THE MARK CONSISTS OF FOUR NON-LATIN CHAR-
ACTERS AND THE NUMBERS ’’199’’.
THE NON-LATIN CHARACTERS IN THE MARK TRANS-
LITERATE TO KANG AI XIAN FENG AND THIS HAS NO
MEANING IN A FOREIGN LANGUAGE.
FOR DIETARY AND NUTRITIONAL SUPPLEMENTS;
DIETARY SUPPLEMENTS (U.S. CLS. 6, 18, 44, 46, 51
AND 52).
FIRST USE 4-1-2002; IN COMMERCE 4-1-2002.
NAPOLEON SHARMA, EXAMINING ATTORNEY
SN 85-336,058. NORTHWEST HAZMAT, INC., SPRING-
FIELD, OR. FILED 6-2-2011.
THE MARK CONSISTS OF STANDARD CHARACTERS
WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,
SIZE, OR COLOR.
FOR SCIENTIFIC TESTING KITS COMPRISED OF
TEST TUBES WHICH CONTAIN IODINE CRYSTALS,
POTASSIUM PREPARATIONS FOR PHARMACEUTICAL
PURPOSES, PIPETTES AND INSTRUCTIONS FOR ANA-
LYZING UNKNOWN SUBSTANCES (U.S. CLS. 6, 18, 44,
46, 51 AND 52).
FIRST USE 10-23-2011; IN COMMERCE 10-23-2011.
ALICE BENMAMAN, EXAMINING ATTORNEY
CLASS 5—(Continued).
SN 85-338,438. AMSTERDAM MOLECULAR THERAPEU-
TICS (AMT) IP B.V., AMSTERDAM, NETHERLANDS,
FILED 6-6-2011.
OWNER OF ERPN CMNTY TM OFC REG. NO. 9599937,
DATED 4-26-2011, EXPIRES 12-15-2020.
OWNER OF U.S. REG. NO. 4,017,988.
THE MARK CONSISTS OF A DARK CIRCLE WITH THE
PHRASE "AMT." DELIVERING CURE INSIDE OF IT.
FOR DIAGNOSTIC PREPARATIONS FOR MEDICAL
PURPOSES, NAMELY, VIRAL SYSTEMS, GENE THER-
APY SYSTEMS, NUCLEIC ACID DELIVERY SYSTEMS,
VIRAL VECTORS, NON-VIRAL VECTORS, GENE THER-
APY VECTORS, NUCLEIC ACID DELIVERY VECTORS,
AND CELLS TRANSFORMED BY VIRAL VECTORS,
NON-VIRAL VECTORS, GENE THERAPY VECTORS
OR NUCLEIC ACID DELIVERY VECTORS FOR MEDI-
CAL PURPOSES; BIOLOGICAL PREPARATIONS FOR
USE IN MEDICAL AND CLINICAL GENE THERAPY,
NUCLEIC ACID-BASED THERAPY AND CELL THER-
APY; CLINICAL MEDICAL REAGENTS FOR USE IN
NUCLEIC ACID-BASED THERAPY, GENE THERAPY,
CELL THERAPY, GENE DIAGNOSIS AND GENE TEST-
ING; PHARMACEUTICAL PREPARATIONS AND VAC-
CINES FOR USE IN NUCLEIC ACID-BASED THERAPY,
GENE THERAPY AND CELL THERAPY (U.S. CLS. 6, 18,
44, 46, 51 AND 52).
MARK SPARACINO, EXAMINING ATTORNEY